FDA Approves POMALYST — Celgene Corporation

# FDA Approves Celgene's POMALYST (pomalidomide) for Multiple Myeloma Treatment Celgene Corporation received FDA approval for POMALYST (pomalidomide), an oral immunomodulatory agent for multiple myeloma, positioning the company to capture significant market share in the growing oncology segment and expand its portfolio beyond existing thalidomide-based therapies. The approval is expected to drive revenue growth and strengthen Celgene's competitive position in the blood cancer market, where demand for novel treatment options remains substantial.